China’s Baidu unveils limited-edition EV with self-driving tech – Nikkei Asia
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $17
Oppenheimer analyst Jay Olson maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and raises the price target from $16 to $17.